Very proud to announce that our second spin-off Vaxxel is laureate of the iLab 2019 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance.
The iLab2019 trophy has been awarded to Vaxxel and its co-founders (Denis CAVERT, Manuel ROSA-CALATRAVA and Julia DUBOIS) in presence of the French Ministry Frédérique VIDAL.
Creation of the new VirPath spin-off VAXXEL
VirParth announces the creation of VAXXEL with the support of the UCBL subsidiaries Lyon Ingenierie Projets and EZUS, the SATT Pulsalys, the Technology Research Platform VirNext and TRANSGENE. Based on our patented polyvalent viral vaccine platform METAVAC® and a pilot process of production using the proprietary DuckCelt®-T17 cell line, VAXXEL is developing an innovative live attenuated vaccine candidate to fight pneumoviruses.
Reviving old drugs to fight viral infections.
VirPath is highlighted in the two months science magazine of INSERM (From science to health, magazine number #43 of June 2019) for its drugs repurposing strategy.
VirPath announces the grant of its patent for the preparation of influenza antigens using an innovative splitting approach for the formulation of novel vaccines by the United States Patent and Trademark Office, notably with regard to the foreseen impact of the current REACH Regulation 1907/2006/EC on the putative prohibition of endocrine disruptors such as Triton X-100.
This patent is issued from a fruitful collaboration with the company CALIXAR that took the operating license, and the Technology Research Platform VirNext.
Results from our collaboration with the Center for Infection and Immunity of Lille (CIIL, U1019-UMR8204) on TLR-5 agonist flagellin and Influenza A Virus.
This study highlights the therapeutic potential of the flagellin to control the replication of the influenza virus.
Results from our collaboration with the Infectious Disease Research Centre (Pr. Guy BOIVIN, Laval University, Quebec) on hMPV infection and NLRP3 inflamasome have been published in Plos Pathogen.
We hereby suggest that the blockade of IL-1β production, by using NLRP3 inflammasome inhibitors, might be a novel potential strategy for the therapy and prevention of hMPV infection.
METAVAC - Maturation Program funded by the Technology Transfer Accelerator Office PULSALYS.
We are proud to announce that the Technology Transfer Accelerator Office PULSALYS will fund our METAVAC R&D program. Based on patented technologies, this program aims to development a new live attenuated viral vaccine and an up scalable avian cell line-based process of production.
The first scientific day of the french influenza research network, ResaFLU, was organized by VirPath.
Launched in July 2018, the French Tech Seed fund is endowed with 400 million euros and managed by BpiFrance. This fund is intended to support Deep-Tech startups. Signia Therapeutics will benefit from an investment by the French Tech Seed fund to complement its current fundraising.
Our last review on drug repurposing approaches for the treatment of influenza viral infection has been accepted in Frontiers in Immunology.
Results from our collaboration with ICBMS/GEMBAS on SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring have been published in Vaccine.
We hereby report an imaging surface plasmon resonance (SPRi) assay for the quantification of both inactivated vaccine influenza antigens and viral particles derived from egg- and cell-based production samples, respectively.
REPURPOSING - Maturation Program funded by the Technology Transfer Accelerator Office PULSALYS.
We are proud to announce that The Technology Transfer Accelerator Office PULSALYS will fund our R&D program on drug repurposing and pre-clinical evaluation of drugs for new antimicrobial indication. These technologies were patented in 2018.
Our publication on the repurposing of Diltiazem as an innovative host targeted influenza inhibitor has been published in Frontiers in Immunology.
Licensed to Signia Therapeutics, Diltiazem is currently evaluated in a phase II clinical trial for the treatment of patients with severe influenza infections in intensive care units (FLUNEXT TRIAL PHRC #15-0442-ClinicalTrials.gov identifier NCT03212716).
Our publication in Journal of Virolgy concerning the functional interactions of cellular p53 and CPSF4 factors with NS1 and their impact on Influenza A virus replication.
Results from our collaborative ANR project OPTIVAC have been published in NPJ Vaccines.
Signia Therapeutics is highlighted in the innovation newsletter of the Centre National de Recherche Scientifique (CNRS), as an innovative start-up working on drug repurposing to counteract respiratory infections.
Andrés Pizzorno' article "Fighting the damocles sword of infectious diseases through drug repurposing" was published in European Biopharmaceutical Review (EBR).